Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

85.50 -0.58 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 267,708
Open 85.31
Bid (Size) 85.05 (5)
Ask (Size) 85.86 (1)
Prev. Close 86.08
Today's Range 83.77 - 85.85
52wk Range 78.02 - 125.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
From BioNTech SE
Via GlobeNewswire
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19

Performance

YTD
-23.90%
-23.90%
1 Month
-1.28%
-1.28%
3 Month
-3.38%
-3.38%
6 Month
-14.75%
-14.75%
1 Year
-20.12%
-20.12%

More News

Read More
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Via Benzinga
Exposures COVID-19
Evaluating BioNTech: Insights From 12 Financial Analysts
Via Benzinga
Evaluating BioNTech: Insights From 15 Financial Analysts
Via Benzinga
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
3 Nasdaq Stocks to Sell in July Before They Crash & Burn
Via InvestorPlace
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
Via InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Via Benzinga
Exposures Product Safety
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
From BioNTech SE
Via GlobeNewswire
GameStop And First Solar Were Among The 10 Biggest Large Cap Losers Last Week (June 16-June 22): Are These In Your Portfolio?
Via Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
Via Benzinga
Exposures Product Safety
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Via Benzinga
Exposures COVID-19 Product Safety
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
What's Going On With Novavax Stock?
Via Benzinga
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From BioNTech SE
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.